Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Net Cash Flow (2021 - 2025)

Prime Medicine's Net Cash Flow history spans 5 years, with the latest figure at -$8.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 112.97% year-over-year to -$8.4 million; the TTM value through Dec 2025 reached -$119.8 million, down 184.69%, while the annual FY2025 figure was -$119.8 million, 184.69% down from the prior year.
  • Net Cash Flow reached -$8.4 million in Q4 2025 per PRME's latest filing, down from $17.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $139.7 million in Q4 2022 to a low of -$90.6 million in Q1 2025.
  • Average Net Cash Flow over 5 years is -$7.3 million, with a median of -$12.9 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 6691.46% in 2022, then plummeted 272.28% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$2.1 million in 2021, then surged by 6691.46% to $139.7 million in 2022, then plummeted by 101.71% to -$2.4 million in 2023, then soared by 2804.36% to $64.5 million in 2024, then crashed by 112.97% to -$8.4 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Net Cash Flow are -$8.4 million (Q4 2025), $17.6 million (Q3 2025), and -$38.4 million (Q2 2025).